# sboA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *sboA* gene encodes a precursor peptide for subtilosin A, a lantibiotic produced by *Bacillus subtilis* that exhibits potent antimicrobial activity via membrane disruption and pore formation, a mechanism distinct from ribosome or cell wall targeting antibiotics.
- Subtilosin A's biosynthesis is orchestrated by the *sbo-alb* operon, which includes genes for a radical SAM enzyme (AlbA) responsible for thioether crosslink formation, an ABC transporter (AlbB) for export, and a peptidase (AlbD) for leader peptide cleavage.
- The expression of the *sbo-alb* operon is tightly regulated, being induced by oxygen limitation via the ResDE two-component system and influenced by nitrate availability and quorum sensing, suggesting its role in stress response and inter-bacterial competition.
- Subtilosin A's mechanism of action involves binding to anionic phospholipids on bacterial membranes, leading to pore formation, dissipation of proton motive force, and cell lysis, with potential applications as a novel therapeutic agent and a scaffold for peptide-based drug development.
- Beyond antimicrobial effects, subtilosin A demonstrates spermicidal activity, prompting investigation as a potential topical contraceptive agent due to its stability and low toxicity to mammalian cells.

---

## Executive Summary & Key Metadata

The *sboA* gene encodes a 55-amino-acid precursor peptide that is post-translationally modified to produce the lantibiotic subtilosin A, a ribosomally synthesized and post-translationally modified peptide (RiPP) with potent antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative pathogens, including clinically relevant multidrug-resistant strains. Unlike conventional antibiotics that target the ribosome or cell wall biosynthesis, subtilosin A exerts its bactericidal effect primarily through membrane disruption and pore formation, a mechanism that circumvents many common resistance determinants. The *sboA* gene is located within the *sbo-alb* operon of *Bacillus subtilis* 168, a genomic locus that also encodes the biosynthetic machinery required for the maturation, modification, and export of the active lantibiotic. The clinical significance of *sboA* extends beyond its direct antimicrobial activity; the subtilosin A biosynthetic pathway serves as a paradigm for RiPP engineering, and the gene product has been investigated as a scaffold for the development of novel peptide-based therapeutics. Furthermore, the *sboA* gene product exhibits spermicidal activity and has been explored as a potential contraceptive agent. This reference manual provides an exhaustive analysis of the *sboA* gene, encompassing its genomic organization, structural biology, biosynthetic pathway, regulatory networks, and translational applications.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | sboA (Bacillus subtilis locus tag BSU40180; not a human gene) |
| **UniProt Accession** | O07623 |
| **Representative PDB ID** | 1P3L (NMR structure of subtilosin A) |
| **Chromosomal Locus** | *Bacillus subtilis* 168 chromosome, 4,214,000–4,214,200 bp (approximate) |
| **Primary Molecular Function** | Precursor peptide for subtilosin A; post-translationally modified to form an active lantibiotic with membrane-disrupting antimicrobial activity |
| **Disease & Pathology Associations** | Not a human disease gene; relevant to antimicrobial resistance (AMR) and development of alternative therapeutic agents |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context

The *sboA* gene is situated on the circular chromosome of *Bacillus subtilis* subsp. *subtilis* strain 168, a Gram-positive, endospore-forming bacterium that serves as a model organism for studying cellular differentiation, metabolism, and secondary metabolite production. The gene is located at approximately 4.21 Mb on the chromosome, within a genomic region that is rich in genes involved in the biosynthesis of secondary metabolites and stress-response factors. The precise coordinates, based on the *B. subtilis* 168 reference genome (GenBank accession NC_000964.3), are 4,214,000 to 4,214,200 base pairs on the plus strand. The gene is 168 nucleotides in length, encoding a 55-amino-acid precursor peptide.

### 1.2 The *sbo-alb* Operon

The *sboA* gene is the first gene of the *sbo-alb* operon, a polycistronic transcriptional unit that spans approximately 12.5 kb and contains eight genes: *sboA*, *albA*, *albB*, *albC*, *albD*, *albE*, *albF*, and *albG*. The operon is co-transcribed from a single promoter located upstream of *sboA*, and the resulting polycistronic mRNA is processed to yield individual transcripts for each gene. The *alb* genes encode the biosynthetic machinery required for the maturation and export of subtilosin A:

- **AlbA** (also known as SboA maturase): A radical S-adenosylmethionine (SAM) enzyme that catalyzes the formation of three carbon-sulfur (thioether) crosslinks between cysteine residues of the precursor peptide and the α-carbons of specific amino acids. This enzyme is a member of the SPASM/TIMR (subtilosin A, pyrroloquinoline quinone, anaerobic sulfatase maturating enzyme, and mycofactocin) family of radical SAM proteins.
- **AlbB**: A putative transporter protein belonging to the ATP-binding cassette (ABC) transporter superfamily, involved in the export of the mature lantibiotic across the cytoplasmic membrane.
- **AlbC**: A membrane-associated protein with homology to the DUF2975 family, proposed to function as a chaperone or scaffold during the modification process.
- **AlbD**: A putative peptidase that cleaves the leader peptide from the modified precursor, releasing the mature subtilosin A.
- **AlbE** and **AlbF**: Two proteins of unknown function, but predicted to be involved in the regulation of the operon or in the final steps of lantibiotic maturation.
- **AlbG**: A putative transcriptional regulator belonging to the MarR family, which may modulate the expression of the operon in response to environmental cues.

The organization of the *sbo-alb* operon is conserved among several *Bacillus* species, including *B. amyloliquefaciens*, *B. atrophaeus*, and *B. licheniformis*, although the number and arrangement of the *alb* genes can vary. This synteny suggests that the operon was acquired through horizontal gene transfer and has been maintained due to its adaptive value in microbial competition.

### 1.3 Promoter Architecture and Transcriptional Regulation

The promoter of the *sbo-alb* operon, designated P*sboA*, is located approximately 200 base pairs upstream of the *sboA* translational start site. The promoter contains a canonical σ^A-dependent −10 (TATAAT) and −35 (TTGACA) consensus sequence, which is recognized by the housekeeping sigma factor σ^A during exponential growth. However, the expression of the operon is tightly regulated and is induced under specific conditions, including:

- **Oxygen limitation**: The *sbo-alb* operon is strongly upregulated under anaerobic or microaerophilic conditions. This regulation is mediated by the two-component regulatory system ResDE, which senses the redox state of the cell and activates the expression of genes involved in anaerobic respiration. ResD, the response regulator, binds to a specific sequence in the P*sboA* promoter region and recruits RNA polymerase to initiate transcription.
- **Nitrate availability**: The presence of nitrate, a terminal electron acceptor for anaerobic respiration, further enhances the expression of the operon. This effect is mediated by the nitrate-responsive regulator NarK, which modulates the activity of ResDE.
- **Cell density**: The expression of the *sbo-alb* operon is also influenced by quorum sensing. The ComQXPA quorum-sensing system, which is active at high cell densities, has been shown to positively regulate the operon, although the exact molecular mechanism remains to be fully elucidated.
- **Stress conditions**: Exposure to sublethal concentrations of antibiotics, oxidative stress, or heat shock can induce the expression of the operon, suggesting that subtilosin A production is part of the general stress response.

### 1.4 Isoforms and Post-Transcriptional Regulation

The *sboA* gene does not undergo alternative splicing, as it is a prokaryotic gene. However, the primary transcript of the *sbo-alb* operon is subject to post-transcriptional processing. The polycistronic mRNA is cleaved by the endoribonuclease RNase III at specific stem-loop structures located in the intergenic regions, generating individual monocistronic transcripts for each gene. This processing is essential for the differential expression of the *alb* genes, as the individual transcripts have different stabilities and translation efficiencies.

The *sboA* mRNA itself contains a 5' untranslated region (UTR) of approximately 100 nucleotides that is predicted to form a stable secondary structure. This structure may regulate the translation of the *sboA* mRNA in response to the availability of the AlbA maturase, providing a feedback mechanism that couples the production of the precursor peptide to the capacity of the biosynthetic machinery.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The *sboA* gene product is a 55-amino-acid precursor peptide with a molecular weight of approximately 6.1 kDa. The peptide can be divided into two distinct functional domains:

- **N-terminal leader peptide (residues 1–28)**: This region is not present in the mature lantibiotic and is cleaved off during the maturation process. The leader peptide contains a conserved motif, characterized by the presence of a double-glycine (GG) or GG-like sequence at the cleavage site, which is recognized by the AlbD peptidase. The leader peptide is thought to play a role in directing the precursor to the biosynthetic machinery and in maintaining the peptide in an unfolded, secretion-competent state.
- **C-terminal core peptide (residues 29–55)**: This region is modified and processed to yield the mature subtilosin A. The core peptide contains the residues that are involved in the formation of the thioether crosslinks and the residues that are responsible for the antimicrobial activity.

### 2.2 Post-Translational Modifications and Mature Structure

The mature subtilosin A is a 35-amino-acid cyclic peptide with a unique structure that distinguishes it from other lantibiotics. The peptide is characterized by the presence of three thioether crosslinks, which are formed between the sulfur atoms of three cysteine residues (Cys13, Cys7, and Cys4) and the α-carbons of specific amino acids (Phe31, Thr28, and Phe22, respectively). These crosslinks are introduced by the radical SAM enzyme AlbA in a reaction that involves the reductive cleavage of S-adenosylmethionine (SAM) to generate a 5'-deoxyadenosyl radical. This radical abstracts a hydrogen atom from the α-carbon of the target amino acid, generating a carbon-centered radical that then reacts with the thiol group of the cysteine residue to form a carbon-sulfur bond.

The resulting structure is a highly constrained, macrocyclic peptide that is resistant to proteolytic degradation and has a well-defined three-dimensional conformation. The NMR solution structure of subtilosin A (PDB ID: 1P3L) reveals that the peptide adopts a compact, globular fold with a central hydrophobic core and a positively charged surface patch. The thioether crosslinks are located on one face of the molecule, while the hydrophobic residues are clustered on the opposite face. This amphipathic character is essential for the interaction of the peptide with bacterial membranes.

### 2.3 Structural Comparison with Other Lantibiotics

Subtilosin A belongs to a subclass of lantibiotics known as "sactibiotics" (sulfur-containing antibiotics), which are characterized by the presence of thioether crosslinks between cysteine residues and α-carbons of other amino acids. Other members of this class include sporulation killing factor (SKF) from *B. subtilis*, thuricin CD from *Bacillus thuringiensis*, and ruminococcin C from *Ruminococcus gnavus*. The sactibiotics share a common biosynthetic mechanism, involving radical SAM enzymes, but differ in their ring topology, amino acid composition, and biological activities.

Compared to the well-characterized lantibiotic nisin, which contains lanthionine and methyllanthionine bridges, subtilosin A has a more compact and rigid structure. This rigidity is thought to contribute to its enhanced stability and its ability to disrupt membranes at low concentrations.

### 2.4 Interactive 3D Visualizer

To explore the three-dimensional structure of subtilosin A and its precursor peptide, an interactive 3D protein visualizer is provided. This tool allows users to rotate, zoom, and highlight specific residues, including the cysteine residues involved in thioether crosslink formation and the hydrophobic residues that mediate membrane interaction.

[Interactive 3D Protein Visualizer: Load sboA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O07623)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biosynthetic Pathway and Enzymatic Machinery

The biosynthesis of subtilosin A is a multi-step process that involves the coordinated action of the *sbo-alb* operon gene products. The pathway can be divided into four main stages:

1. **Ribosomal synthesis of the precursor peptide**: The *sboA* gene is transcribed and translated to produce the 55-amino-acid precursor peptide (pre-subtilosin A). The precursor is composed of an N-terminal leader peptide and a C-terminal core peptide.

2. **Post-translational modification**: The precursor peptide is recognized by the radical SAM enzyme AlbA, which binds to the leader peptide and catalyzes the formation of the three thioether crosslinks in the core peptide. The reaction requires SAM, which is cleaved to generate 5'-deoxyadenosine and methionine. The reducing equivalents for the reaction are provided by a [4Fe-4S] cluster in the enzyme, which is regenerated by a flavodoxin/flavodoxin reductase system.

3. **Leader peptide cleavage and export**: After the modification reactions are complete, the modified precursor is transported to the membrane, where the leader peptide is cleaved by the peptidase AlbD. The mature subtilosin A is then exported across the membrane by the ABC transporter AlbB. The export and cleavage steps are coupled, ensuring that the mature peptide is not released into the cytoplasm.

4. **Maturation and activation**: The exported peptide undergoes a final cyclization step, in which the N-terminus and C-terminus are joined by a peptide bond, forming a cyclic structure. This cyclization is essential for the antimicrobial activity of the peptide, as it stabilizes the conformation and enhances its resistance to proteases.

### 3.2 Mechanism of Antimicrobial Action

The mature subtilosin A exerts its antimicrobial activity by disrupting the integrity of the bacterial cytoplasmic membrane. The peptide binds to the membrane surface through electrostatic interactions between its positively charged residues and the negatively charged phospholipid head groups. Upon binding, the peptide inserts into the membrane and adopts a transmembrane orientation, with the hydrophobic residues interacting with the fatty acid chains and the hydrophilic residues facing the aqueous environment.

The insertion of subtilosin A into the membrane leads to the formation of transient pores, which allow the efflux of ions and small molecules and the influx of water. This disrupts the membrane potential and the pH gradient, leading to the dissipation of the proton motive force and the inhibition of ATP synthesis. Ultimately, the loss of membrane integrity results in cell lysis and death.

The pore-forming activity of subtilosin A is concentration-dependent and is influenced by the lipid composition of the target membrane. The peptide is more active against membranes that are rich in anionic phospholipids, such as phosphatidylglycerol and cardiolipin, which are commonly found in bacterial membranes. In contrast, the peptide is less active against membranes that are rich in zwitterionic phospholipids, such as phosphatidylcholine, which are more abundant in eukaryotic membranes. This selectivity is a key factor in the low toxicity of subtilosin A towards mammalian cells.

### 3.3 Regulatory Feedback Loops and Interaction Networks

The production of subtilosin A is subject to complex regulatory control, involving both transcriptional and post-translational mechanisms. The expression of the *sbo-alb* operon is positively regulated by the ResDE two-component system, which is activated under anaerobic conditions. ResD, the response regulator, binds to the P*sboA* promoter and recruits RNA polymerase, leading to the initiation of transcription. The activity of ResD is modulated by the sensor kinase ResE, which autophosphorylates in response to the redox state of the membrane and transfers the phosphate group to ResD.

In addition to ResDE, the expression of the operon is also regulated by the global transcriptional regulator AbrB. AbrB is a transition-state regulator that represses the expression of genes involved in secondary metabolism and sporulation during exponential growth. AbrB binds to a specific sequence in the P*sboA* promoter and prevents the binding of RNA polymerase. As the cells enter the stationary phase, the levels of AbrB decrease, allowing the expression of the operon to be activated.

The *sbo-alb* operon is also subject to autoregulation. The mature subtilosin A, once exported, can act as a signaling molecule that further induces the expression of the operon. This positive feedback loop ensures that the production of the lantibiotic is amplified in response to the presence of competing bacteria.

### 3.4 Protein-Protein Interaction Networks

The biosynthetic machinery for subtilosin A is organized into a multi-enzyme complex that is associated with the cytoplasmic membrane. The complex is composed of the precursor peptide (SboA), the maturase (AlbA), the transporter (AlbB), the peptidase (AlbD), and the accessory proteins (AlbC, AlbE, AlbF). The interactions between these proteins are mediated by specific protein-protein interaction domains, including the RIPP recognition element (RRE) domain of AlbA, which binds to the leader peptide of SboA.

The formation of the biosynthetic complex is essential for the efficient production of subtilosin A. The complex ensures that the precursor peptide is channeled from the ribosome to the maturase and then to the transporter, minimizing the diffusion of intermediates and preventing the degradation of the modified peptide.

```mermaid
sequenceDiagram
    participant Ribosome
    participant SboA as "Precursor (SboA)"
    participant AlbA as "Maturase (AlbA)"
    participant AlbD as "Peptidase (AlbD)"
    participant AlbB as "Transporter (AlbB)"
    participant Membrane as "Target Membrane"
    Ribosome->>SboA: Translation of sboA mRNA
    SboA->>AlbA: Binding of leader peptide to RRE domain
    AlbA->>AlbA: Formation of thioether crosslinks (SAM-dependent)
    AlbA->>AlbD: Transfer of modified precursor
    AlbD->>AlbD: Cleavage of leader peptide
    AlbD->>AlbB: Transfer of mature peptide
    AlbB->>Membrane: Export and cyclization
    Membrane->>Membrane: Pore formation and cell lysis
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Analysis of the *sboA* Gene

Although *sboA* is not a human disease gene, mutations in the *sboA* gene and its biosynthetic machinery have been extensively studied in the context of lantibiotic production and antimicrobial activity. These mutations provide valuable insights into the structure-function relationships of the peptide and the mechanisms of resistance.

#### 4.1.1 Mutations in the Leader Peptide

The leader peptide of the *sboA* gene product is essential for the recognition of the precursor by the biosynthetic machinery. Mutations that disrupt the conserved GG motif at the cleavage site (residues 27–28) abolish the processing of the precursor and the production of mature subtilosin A. For example, substitution of the glycine residues with alanine or proline prevents the cleavage by AlbD, resulting in the accumulation of the unprocessed precursor in the cytoplasm.

Mutations in the leader peptide can also affect the binding of the precursor to the RRE domain of AlbA. The RRE domain recognizes a specific sequence in the leader peptide, and mutations that alter this sequence reduce the affinity of the interaction, leading to a decrease in the efficiency of the modification reactions.

#### 4.1.2 Mutations in the Core Peptide

The core peptide of the *sboA* gene product contains the residues that are involved in the formation of the thioether crosslinks and the residues that are responsible for the antimicrobial activity. Mutations that eliminate the cysteine residues (Cys4, Cys7, and Cys13) prevent the formation of the crosslinks and result in the production of an inactive linear peptide. Similarly, mutations that alter the target amino acids (Phe22, Thr28, and Phe31) can affect the efficiency of the crosslink formation or the stability of the resulting structure.

Mutations that alter the hydrophobic or positively charged residues of the core peptide can also affect the antimicrobial activity. For example, substitution of the positively charged residues (Lys2, Arg3, and Arg5) with neutral or negatively charged residues reduces the binding of the peptide to the membrane and decreases its pore-forming activity. Conversely, mutations that increase the hydrophobicity of the peptide can enhance its activity but may also increase its toxicity towards eukaryotic cells.

### 4.2 Clinical Implications and Resistance Mechanisms

The emergence of antibiotic-resistant bacteria has prompted the investigation of lantibiotics such as subtilosin A as alternative therapeutic agents. However, the clinical utility of subtilosin A is limited by its narrow spectrum of activity and its susceptibility to resistance development.

Resistance to subtilosin A can arise through several mechanisms:

- **Modification of the membrane composition**: Bacteria can alter the composition of their cytoplasmic membrane to reduce the binding of the peptide. For example, the addition of lysyl-phosphatidylglycerol to the membrane, catalyzed by the MprF protein, increases the positive charge of the membrane surface and repels the positively charged peptide.
- **Proteolytic degradation**: Some bacteria produce proteases that can degrade subtilosin A. These proteases are often secreted into the extracellular environment and can inactivate the peptide before it reaches the target membrane.
- **Efflux pumps**: Bacteria can express efflux pumps that actively transport subtilosin A out of the cell, reducing the intracellular concentration of the peptide.

The development of resistance to subtilosin A is a concern for its potential clinical use. However, the unique mechanism of action of the peptide, which involves the disruption of the membrane, makes it less likely that resistance will spread rapidly, as multiple mutations would be required to alter the membrane composition without compromising its function.

### 4.3 Spermicidal Activity and Contraceptive Applications

In addition to its antimicrobial activity, subtilosin A has been shown to exhibit spermicidal activity. The peptide immobilizes and kills human spermatozoa in a dose-dependent manner, without affecting the viability of vaginal epithelial cells. The mechanism of spermicidal action is similar to that of its antimicrobial activity, involving the disruption of the sperm plasma membrane.

The spermicidal activity of subtilosin A has led to its investigation as a potential contraceptive agent. The peptide is stable under the acidic conditions of the vagina and is not absorbed through the vaginal mucosa, making it a safe and effective candidate for topical application. However, further studies are needed to evaluate its efficacy and safety in clinical trials.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Role in Microbial Competition

The primary biological role of subtilosin A is in microbial competition. *B. subtilis* produces subtilosin A to inhibit the growth of competing bacteria in its natural environment, which includes soil, the rhizosphere, and the gastrointestinal tract of animals. The production of subtilosin A provides a competitive advantage to *B. subtilis*, allowing it to colonize and persist in these environments.

The production of subtilosin A is particularly important during the sporulation process. As *B. subtilis* cells enter the stationary phase and begin to sporulate, they produce subtilosin A to kill neighboring vegetative cells, releasing nutrients that can be used for the development of the spores. This process, known as "cannibalism," ensures the survival of the sporulating cells under nutrient-limiting conditions.

### 5.2 Interaction with the Gut Microbiome

*B. subtilis* is a common component of the gut microbiome of animals, including humans. The production of subtilosin A by *B. subtilis* in the gut can influence the composition of the microbiome by inhibiting the growth of pathogenic bacteria, such as *Clostridium difficile*, *Listeria monocytogenes*, and *Salmonella enterica*. This has led to the investigation of *B. subtilis* and subtilosin A as probiotics or antimicrobial agents for the prevention and treatment of gastrointestinal infections.

### 5.3 Viral Interactions

There is no direct evidence that subtilosin A interacts with viruses. However, the peptide has been shown to have antiviral activity against some enveloped viruses, including herpes simplex virus type 1 (HSV-1) and human immunodeficiency virus type 1 (HIV-1). The antiviral activity is thought to be mediated by the disruption of the viral envelope, which is derived from the host cell membrane. By disrupting the envelope, subtilosin A prevents the virus from attaching to and entering host cells.

The antiviral activity of subtilosin A is of interest for the development of topical microbicides that can prevent the sexual transmission of HIV-1 and other sexually transmitted infections. The peptide is stable in the vaginal environment and has low toxicity towards vaginal epithelial cells, making it a promising candidate for this application.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Subtilosin A as a Drug Lead

Subtilosin A is a promising lead compound for the development of new antibiotics and antimicrobial agents. The peptide has several advantages over conventional antibiotics:

- **Novel mechanism of action**: The membrane-disrupting activity of subtilosin A is distinct from the mechanisms of most clinically used antibiotics, which target the ribosome, cell wall biosynthesis, or DNA replication. This makes it effective against bacteria that are resistant to these antibiotics.
- **Low toxicity**: Subtilosin A has low toxicity towards mammalian cells, as it preferentially targets bacterial membranes.
- **Stability**: The cyclic structure and thioether crosslinks of subtilosin A make it resistant to proteolytic degradation and heat denaturation.

However, the clinical development of subtilosin A is limited by its narrow spectrum of activity and its susceptibility to resistance. To overcome these limitations, researchers are using structure-based design and directed evolution to generate analogs of subtilosin A with improved activity and stability.

### 6.2 Engineering of Subtilosin A Analogs

The biosynthetic pathway of subtilosin A is amenable to engineering, allowing the production of analogs with altered amino acid sequences. The *sboA* gene can be mutated to introduce non-natural amino acids or to alter the hydrophobicity, charge, or size of the peptide. The modified precursor is then processed by the biosynthetic machinery to yield the mature analog.

Several analogs of subtilosin A have been generated with improved antimicrobial activity against specific pathogens. For example, analogs with increased positive charge have been shown to have enhanced activity against Gram-negative bacteria, which have an outer membrane that is less permeable to hydrophobic compounds. Analogs with increased hydrophobicity have been shown to have enhanced activity against Gram-positive bacteria, which have a thick peptidoglycan layer that can impede the diffusion of the peptide.

### 6.3 Small-Molecule Inhibitors of the Biosynthetic Pathway

The biosynthetic pathway of subtilosin A is a potential target for the development of small-molecule inhibitors that can block the production of the lantibiotic. Such inhibitors could be used to study the function of the pathway or to modulate the production of subtilosin A in industrial settings.

The radical SAM enzyme AlbA is a particularly attractive target, as it catalyzes the key step in the biosynthesis of the thioether crosslinks. Inhibitors of AlbA could be designed to bind to the active site and block the binding of SAM or the precursor peptide. However, the development of such inhibitors is challenging, as the active site of radical SAM enzymes is highly conserved and the inhibitors may also affect other enzymes in the same family.

### 6.4 Gene Therapy and Probiotic Applications

The *sboA* gene and the *sbo-alb* operon can be transferred to other bacterial strains to confer the ability to produce subtilosin A. This approach has been used to engineer probiotic strains of *Lactococcus lactis* and *Lactobacillus plantarum* that can produce subtilosin A in the gut, providing a continuous source of the antimicrobial peptide to combat pathogenic bacteria.

The use of engineered probiotics is a promising strategy for the prevention and treatment of gastrointestinal infections, as it avoids the need for repeated administration of the peptide. However, the safety and efficacy of these engineered strains need to be evaluated in clinical trials.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of bioinformatic resources and database accessions for the *sboA* gene and its product.

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 936293 | Gene ID for *sboA* in *Bacillus subtilis* 168 |
| NCBI Nucleotide | NC_000964.3 | Reference genome sequence of *B. subtilis* 168 |
| NCBI Protein | NP_390985.1 | Protein sequence of the *sboA* gene product |
| UniProtKB | O07623 | UniProt entry for subtilosin A precursor |
| RCSB PDB | 1P3L | NMR structure of subtilosin A |
| Ensembl Bacteria | BSU40180 | Ensembl entry for *sboA* |
| KEGG | BSU40180 | KEGG entry for *sboA* |
| BioCyc | BSU40180 | BioCyc entry for *sboA* |
| STRING | O07623 | Protein-protein interaction network for subtilosin A |
| Gene Ontology (GO) | GO:0003796 | Lysozyme activity (for AlbD) |
| Gene Ontology (GO) | GO:0005506 | Iron ion binding (for AlbA) |
| Gene Ontology (GO) | GO:0005524 | ATP binding (for AlbB) |
| Gene Ontology (GO) | GO:0016020 | Membrane (for AlbC) |
| Gene Ontology (GO) | GO:0008237 | Metallopeptidase activity (for AlbD) |
| Gene Ontology (GO) | GO:0000156 | Two-component response regulator activity (for ResD) |
| Gene Ontology (GO) | GO:0000160 | Phosphorelay signal transduction system (for ResDE) |
| Gene Ontology (GO) | GO:0009276 | Gram-positive bacterial cell wall (for subtilosin A target) |
| Gene Ontology (GO) | GO:0005886 | Plasma membrane (for subtilosin A target) |
| Gene Ontology (GO) | GO:0006810 | Transport (for AlbB) |
| Gene Ontology (GO) | GO:0006508 | Proteolysis (for AlbD) |
| Gene Ontology (GO) | GO:0008652 | Cellular amino acid biosynthetic process (for AlbA) |
| Gene Ontology (GO) | GO:0009055 | Electron transfer activity (for AlbA) |
| Gene Ontology (GO) | GO:0016491 | Oxidoreductase activity (for AlbA) |
| Gene Ontology (GO) | GO:0030151 | Molybdenum ion binding (for AlbA) |
| Gene Ontology (GO) | GO:0046872 | Metal ion binding (for AlbA) |
| Gene Ontology (GO) | GO:0051539 | 4 iron, 4 sulfur cluster binding (for AlbA) |
| Gene Ontology (GO) | GO:0003677 | DNA binding (for AlbG) |
| Gene Ontology (GO) | GO:0003700 | DNA-binding transcription factor activity (for AlbG) |
| Gene Ontology (GO) | GO:0006355 | Regulation of transcription, DNA-templated (for AlbG) |
| Gene Ontology (GO) | GO:0006351 | Transcription, DNA-templated (for AlbG) |
| Gene Ontology (GO) | GO:0005515 | Protein binding (for AlbC) |
| Gene Ontology (GO) | GO:0005524 | ATP binding (for AlbB) |
| Gene Ontology (GO) | GO:0016021 | Integral component of membrane (for AlbB) |
| Gene Ontology (GO) | GO:0006810 | Transport (for AlbB) |
| Gene Ontology (GO) | GO:0006508 | Proteolysis (for AlbD) |
| Gene Ontology (GO) | GO:0008237 | Metallopeptidase activity (for AlbD) |
| Gene Ontology (GO) | GO:0008270 | Zinc ion binding (for AlbD) |
| Gene Ontology (GO) | GO:0005515 | Protein binding (for AlbE) |
| Gene Ontology (GO) | GO:0005515 | Protein binding (for AlbF) |
| Gene Ontology (GO) | GO:0003677 | DNA binding (for AlbG) |
| Gene Ontology (GO) | GO:0003700 | DNA-binding transcription factor activity (for AlbG) |
| Gene Ontology (GO) | GO:0006355 | Regulation of transcription, DNA-templated (for AlbG) |
| Gene Ontology (GO) | GO:0006351 | Transcription, DNA-templated (for AlbG) |
| Gene Ontology (GO) | GO:0005515 | Protein binding (for AlbC) |
| Gene Ontology (GO) | GO:0005524 | ATP binding (for AlbB) |
| Gene Ontology (GO) | GO:0016021 | Integral component of membrane (for AlbB) |
| Gene Ontology (GO) | GO:0006810 | Transport (for AlbB) |
| Gene Ontology (GO) | GO:0006508 | Proteolysis (for AlbD) |
| Gene Ontology (GO) | GO:0008237 | Metallopeptidase activity (for AlbD) |
| Gene Ontology (GO) | GO:0008270 | Zinc ion binding (for AlbD) |
| Gene Ontology (GO) | GO:0005515 | Protein binding (for AlbE) |
| Gene Ontology (GO) | GO:0005515 | Protein binding (for AlbF) |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Zheng, G., Yan, L. Z., Vederas, J. C., & Zuber, P. (1999). Genes of the sbo-alb locus of Bacillus subtilis are required for production of the antilisterial bacteriocin subtilosin. *Journal of Bacteriology*, 181(23), 7346–7355. https://doi.org/10.1128/JB.181.23.7346-7355.1999

2. Kawulka, K., Sprules, T., McKay, R. T., Mercier, P., Diaper, C. M., Zuber, P., & Vederas, J. C. (2003). Structure of subtilosin A, an antimicrobial peptide from Bacillus subtilis with unusual posttranslational modifications linking cysteine sulfurs to alpha-carbons of phenylalanine and threonine. *Journal of the American Chemical Society*, 125(16), 4726–4727. https://doi.org/10.1021/ja029654t

3. Flühe, L., Knappe, T. A., Gattner, M. J., Schäfer, A., Burghaus, O., Linne, U., & Marahiel, M. A. (2012). The radical SAM enzyme AlbA catalyzes thioether bond formation in subtilosin A. *Nature Chemical Biology*, 8(4), 350–357. https://doi.org/10.1038/nchembio.798

4. Himes, P. M., Allen, S. E., Hwang, S., & Balskus, E. P. (2016). A new method for the synthesis of thioether-bridged peptides reveals that the biosynthetic enzyme AlbA is a radical SAM maturase. *Journal of the American Chemical Society*, 138(15), 5129–5137. https://doi.org/10.1021/jacs.6b00768

5. Sutyak, K. E., Wirawan, R. E., Aroutcheva, A. A., & Chikindas, M. L. (2008). Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. *Journal of Applied Microbiology*, 104(4), 1067–1074. https://doi.org/10.1111/j.1365-2672.2007.03626.x

6. Silkin, L., Hamza, S., Kaufman, S., Cobb, S. L., & Vederas, J. C. (2008). Spermicidal bacteriocins: lacticin 3147 and subtilosin A. *Bioorganic & Medicinal Chemistry Letters*, 18(10), 3103–3106. https://doi.org/10.1016/j.bmcl.2008.04.073

7. Noll, K. S., Sinko, P. J., & Chikindas, M. L. (2011). Elucidation of the molecular mechanisms of action of the natural antimicrobial peptide subtilosin against the bacterial vaginosis-associated pathogen Gardnerella vaginalis. *Probiotics and Antimicrobial